Skip to main content
Respiratory Syncytial Virus InfectionsLungs and breathingDrugPhase 2

What this study is

The main purpose of this study is to investigate the antiviral effect of S-337395 compared with placebo among nonhospitalized adult participants with high-risk factors for progression to severe RSV infection starting intervention within 72 hours of RSV symptom onset.

What's being tested

  • S-337395

    Intervention · DRUG

    S-337395 will be administered per schedule specified in the arm description.

  • Placebo

    Intervention · DRUG

    Placebo matched to S-337395 will be administered per schedule specified in the arm description.

Study details

Official title
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease
Sponsor
Shionogi
Conditions
Respiratory Syncytial Virus Infections
Enrolling
192 people
Starts
2025-12-11
Est. completion
2026-12-30
Design
Quadruple-blind, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗